Stephen V Liu, Associate Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“In radioiodine refractory BRAF V600E thyroid cancer, phase III study of dabrafenib + trametinib reported The Lancet Oncology.
PFS 12.8m (3.7m with placebo, HR 0.38), RR 57%, OS not significant.
Most common AE pyrexia (48%), most common G3+ AE pneumonia (8%).”
Title: Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Ming Gao, Young Joo Park, Chia-Chi Lin,Monika K Krzyzanowska, Zhiyong Li, Hui-Jen Tsai, Feng Shi, Jianwu Qin, Swee Hsia Choong, Yansong Lin, Yuan Zhang, Jin H Kang, Ana O Hoff, Monique Tan, Michael Roughton, Michaela Paul, Lori J Wirth
Other articles about thyroid cancer on OncoDaily.